NeurogesX is touting positive data from the second late-stage study of NGX-4010, a dermal patch therapy for patients with postherpetic neuralgia. The study hit its primary endpoint with a 32 percent reduction in pain from baseline from a single 60-minute application of NGX-4010 as compared to a 24 percent reduction in pain in the control group. The study also hit all of its secondary endpoints.
- see theÂ releaseÂ on the trial results
NeurogesX blueprints IPO plans. Report